NCT00006226View on ClinicalTrials.gov

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

December 31, 2007

Conditions
B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
Interventions
DRUG

thalidomide

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006226 - Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter